8) Rizvi H, Sanchez-Vega F, La K, et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing [J]. J Clin Oncol. 2018,...
J.A.; et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn. Pathol. 2016, 11, 95.
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing [J]. J Clin...
8) Rizvi H, Sanchez-Vega F, La K, et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing [J]. J Clin Oncol. 2018,...
^Snyder, A., et al. “Genetic basis for clinical response to CTLA-4 blockade in melanoma.”N Engl J Med 371.23(2014): p. 2189-2199.^Rizvi, N.A., et al. “Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.^Campesato, L....
Biochimica et biophysica acta: BBA: International journal of biochemistry, biophysics and molecular biololgy. Proteins and ProteomicsSingh,N. et al. (2011) TMBHMM: a frequency profile based HMM for predicting the topology of transmembrane beta barrel proteins and the exposure status of transmembrane...
^Snyder, A., et al. “Genetic basis for clinical response to CTLA-4 blockade in melanoma.”N Engl J Med 371.23(2014): p. 2189-2199. ^Rizvi, N.A., et al. “Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. ...
We present here TMBHMM, a computational method based on a hidden Markov model for predicting the structural topology of putative TMBs from sequence. In addition to predicting transmembrane strands, TMBHMM also predicts the exposure status (i.e., exposed to the membrane or hidden in the protein ...
[20].Roach C, Zhang N, Corigliano E, et al. Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer[J]. Applied Immunohistochemistry & Molecular Morphology, 2016, 24(6): 392-397. ...
“Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.” J Clin Oncol 36.7( 2018): p. 633-641. ^中国抗癌协会肿瘤标志专业...